Close
Solutions
Online Inquiry
Global Services

One-Stop TCR-T Therapy Development Solutions

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Solutions Platforms Advantages Resources Related Sections

In the past decade, tremendous progress has been made in the field of immunotherapy, especially in the field of T cell therapy. This method uses engineered T cells with artificial chimeric antigen receptors (CAR) as an example, which can recognize specific proteins expressed on the surface of tumor cells, resulting in rapid activation and killing of tumor cells. Although clinical success has been achieved in a few tumor types, the types of surface proteins that can be targeted by this technology are limited, which severely limits the development of CAR-T cells for multiple tumor types. Besides, the targeted surface proteins so far are also expressed on normal cells, leading to CAR-T-mediated killing of non-cancer cells and potentially life-threatening side effects related to the intensity of the subsequent immune response.

To solve the problem of the scope and selectivity of CAR-T, researchers are turning to a method of engineering T cells based on T cell receptors (TCR-T). The ability of TCR to selectively recognize target cells comes from its unique ability to recognize cell surface "antigens". These antigens can be used as selective identifiers for malignant cells, and more and more tumor-related antigens are being identified, enabling the engineering of a potent and selective TCR-T directed against cancer.

As the leading cell therapeutics biotech that provides cell therapy related services, Creative Biolabs masters the most advanced CAR/TCR technology. With state-of-art TCR development platforms and advanced technologies, Creative Biolabs is capable of offering a broad range of TCR-T early development services, including TCR engineered T cell biomarker identification and selection, design, construction, and analysis. Moreover, our one-stop TCR development services also provide you the preclinical test.

TCR-T Therapy Development Solutions

TCR Biomarker Identification & Selection TCR Generation & Optimization TCR Design & Construction TCR Gene Packaging & Delivery TCR In Vitro Assay TCR-T Preclinical In Vivo Assay TCR Analysis TCR Clinical Applications
One-Stop TCR-T Therapy Development
  • De novo discovery of potential cancer biomarkers by multiple gene and protein analysis technologies
  • Selection of the most suitable TCR-T therapy targets with greater potency and lower toxicity
One-Stop TCR-T Therapy Development
  • TCR Generated from patient's TIL, phage display, and in vivo system
  • TCR Affinity Optimization/TCR Affinity Maturation
One-Stop TCR-T Therapy Development
  • Design and construction of classical TCR of different modification
  • Customized TCR design
  • TCR-T construction
One-Stop TCR-T Therapy Development
  • Both lentiviral vectors and retroviral vectors are avalible
  • GMP vircus manufacturing for clinical trials and applications
  • Strict quality control
One-Stop TCR-T Therapy Development
  • T cell validation assay, T cell activation assay, Cytokine release assay, Cytotoxicity assay, TCR specificity assay
One-Stop TCR-T Therapy Development
  • Construction of animal models, T cell trafficking test, T cell persistence test, Efficacy test, Safety/toxicity evaluation
One-Stop TCR-T Therapy Development
  • TCR Repertoire Sequencing, TCR Vβ Repertoire Analysis, MHC-peptide Tetramer, MHC Tetramer Assays, TCR Clonality Assessment, TCR Clonality Quantitation and CDR3 Size Diversity Technology
One-Stop TCR-T Therapy Development
  • TCR Clinical Diagnostics
  • TCR Clinical Therapeutics

TCR-T Cell Platforms

With high-affinity TCR technology, Creative Biolabs is capable of identifying the candidate target tumor antigen and the sequence of tumor-specific TCR to create tumor-specific T cells.

CellRapeutics™ TCR Technology

To discover novel antigens of TCRs from viral or human genome-wide libraries, our scientists developed an advanced T-Scan platform, a T cell-based, high-throughput screening approach to identify functional T cell-specific epitopes for studying T cell responses.

T-Scan Platform for High-throughput Identification of T Cell-specific Epitopes

In our Tseeking™ platform, we have designed a new TCR reporter cell line cassette for T cell activation that can sensitively read the specificity of any number of T cell-activating receptors, including but not limited, to CAR-T and TCR-T, and their ligands.

Tseeking™ Platform for TCR/Ligand Discovery

Creative Biolabs provides a cutting-edge platform for Antibody-Coupled T Cell Receptor (ACTR) technology, offering universal engineered T cell therapies that can be combined with various tumor-targeting antibodies to treat a wide range of cancers.

Antibody-Coupled T Cell Receptor (ACTR) Platform

Creative Biolabs offers a comprehensive range of services for the development of off-the-shelf gamma delta (γδ) T cell therapies, including isolation, activation, expansion, characterization, and engineering of Vδ1 and Vδ2 T cells, as well as custom γδ bispecific T-cell engagers for cancer treatment.

Gamma Delta (γδ) T cell Platform

Creative Biolabs provides custom development services for tetravalent bispecific (TetraBi) T-cell engagers, leveraging their experienced team and advanced technology to create effective cancer therapies with lower immunogenicity, stronger binding affinity, and higher safety.

Tetravalent Bispecific (TetraBi) T-cell Engager Platform

Highlights & Advantages

  • Specificity and Precision
    TCR-engineered T cells target specific antigens on cancer cells, enhancing treatment accuracy and minimizing harm to healthy cells.
  • Enhanced Efficacy
    High-affinity TCRs boost the immune response, leading to better clinical outcomes.
  • Reduced Off-Target Effects
    By focusing on intracellular antigens, TCR-T cells minimize risks to normal cells.
  • Versatile Applications
    Effective for various cancers, including those with limited surface protein targets for CAR-T cells.
  • Long-Lasting Immunity
    Potential for durable responses and long-term cancer protection through memory cell formation.
  • Scalability and Reproducibility
    Advanced techniques ensure scalable, high-quality TCR-T cell production for clinical use.
  • Comprehensive Services
    Creative Biolabs provides end-to-end solutions, including biomarker identification, TCR generation, design, optimization, gene packaging, in vitro and in vivo assays, and preclinical tests.
  • Custom Solutions
    Tailored TCR designs and optimized affinities enhance efficacy and safety for each patient.

Resources

Use the resources in our library to help you understand your options and make critical decisions for your study.

VideosPodcasts Support Knowledge
TCR-Engineered T Cell Therapy in Cancer Treatment

TCR-T cell therapy is an emerging form of cancer immunotherapy that modifies T cells to recognize and attack cancer cells more effectively. T cells are genetically engineered to express high-affinity T-cell receptors (TCRs) that can bind to specific antigens on cancer cells, triggering immune responses to eliminate the tumors. While promising for treating myeloma, myeloid malignancies, and solid tumors, this therapy faces challenges including safety concerns, potential off-target effects, and the need for improved manufacturing processes. Ongoing clinical trials continue to refine TCR-T therapy, highlighting both its potential and the hurdles that must be overcome for widespread clinical application.

Overview of Bispecific T-Cell Engager

Bispecific T cell engagers are antibody molecules with two antigen-binding sites, allowing them to simultaneously bind to tumor-associated antigens (TAA) on tumor cells and CD3 molecules on T cells. This dual binding redirects T cells to the tumor cell surface, activating T cell proliferation and cytotoxicity to kill tumor cells. These engagers consist of two single-chain variable fragments (scFv) and have a smaller molecular weight than conventional antibodies. Their mechanism of action involves activating T cells via CD3 binding, recruiting T cells to tumor cells, and inducing apoptosis through the release of effector molecules. Despite advantages such as using endogenous T cells and targeting diverse tumor antigens, bispecific T cell engagers face challenges like short half-life, potential toxicity, and immunosuppressive tumor environments. Ongoing developments aim to optimize their specificity, pharmacokinetics, and reduce adverse effects to enhance their therapeutic potential.

T Cell-based Immunotherapies

Based on the significant roles of T cells in the immune system, many small-molecule drugs targeting T cells and T-cell based immunotherapies have been developed for the treatment of intractable diseases including autoimmune diseases and cancer. T cell-based immunotherapies mainly utilize the mechanisms of T cell-mediated immune responses and the effects of some other immune cells such as dendritic cells (DCs), natural killer (NK) cells, and macrophages.

Adoptive Transfer of Genetically Engineered T Cells

Adoptive cell transfer (ACT) of engineered T cells is a cutting-edge therapeutic approach revolutionizing cancer treatment. This innovative method involves modifying T cells, a key component of the immune system, to enhance their ability to target and eliminate cancer cells. By introducing genetically engineered T cells into patients, researchers aim to bolster the immune response against cancer, offering a personalized and potentially curative treatment option. This groundbreaking technology holds promise for addressing various malignancies and represents a significant stride towards more effective and precise cancer therapies.

Related Sections

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.